Jason R Stubbs

Summary

Affiliation: University of Kansas Medical Center
Country: USA

Publications

  1. pmc Serum Trimethylamine-N-Oxide is Elevated in CKD and Correlates with Coronary Atherosclerosis Burden
    Jason R Stubbs
    The Kidney Institute, University of Kansas Medical Center, Kansas City, Kansas Department of Internal Medicine, Division of Nephrology and Hypertension, University of Kansas Medical Center, Kansas City, Kansas
    J Am Soc Nephrol 27:305-13. 2016
  2. pmc Decreased conversion of 25-hydroxyvitamin D3 to 24,25-dihydroxyvitamin D3 following cholecalciferol therapy in patients with CKD
    Jason R Stubbs
    The Kidney Institute, University of Kansas Medical Center, Kansas City, Kansas
    Clin J Am Soc Nephrol 9:1965-73. 2014
  3. pmc Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease
    Jason R Stubbs
    The Kidney Institute, University of Kansas Medical Center, Kansas City, KS 66160, USA
    J Bone Miner Res 27:38-46. 2012
  4. doi request reprint Is fibroblast growth factor 23 a harbinger of mortality in CKD?
    Jason R Stubbs
    Division of Nephrology and Hypertension, University of Kansas Medical Center, 3901 Rainbow Blvd, Mail Stop 3002, Kansas City, KS 66160, USA
    Pediatr Nephrol 27:697-703. 2012
  5. pmc Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD
    Jason R Stubbs
    3901 Rainbow Boulevard, MS 3002, Kansas City, KS 66160, USA
    J Am Soc Nephrol 21:353-61. 2010
  6. doi request reprint Does it matter how parathyroid hormone levels are suppressed in secondary hyperparathyroidism?
    Jason R Stubbs
    Division of Nephrology and Hypertension and The Kidney Institute, University of Kansas Medical Center, Kansas City, Kansas, USA
    Semin Dial 24:298-306. 2011
  7. pmc Dietary phosphate restriction suppresses phosphaturia but does not prevent FGF23 elevation in a mouse model of chronic kidney disease
    Shiqin Zhang
    The Kidney Institute, University of Kansas Medical Center, Kansas City, Kansas, USA
    Kidney Int 84:713-21. 2013
  8. ncbi request reprint Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice
    Jason R Stubbs
    The Kidney Institute, University of Kansas Medical Center, Kansas City, KS 66160, USA
    J Am Soc Nephrol 18:2116-24. 2007
  9. ncbi request reprint Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D
    Shiguang Liu
    Department of Internal Medicine and the Kidney Institute, University of Kansas Medical Center, 3901 Rainbow Boulevard, Room 6020 WHE, MS 3018, Kansas City, KS 66160, USA
    J Am Soc Nephrol 17:1305-15. 2006
  10. pmc FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy
    Chad D Touchberry
    Muscle Biology Group, School of Medicine, University of Missouri Kansas City, Kansas City, MO 64108, USA
    Am J Physiol Endocrinol Metab 304:E863-73. 2013

Collaborators

Detail Information

Publications11

  1. pmc Serum Trimethylamine-N-Oxide is Elevated in CKD and Correlates with Coronary Atherosclerosis Burden
    Jason R Stubbs
    The Kidney Institute, University of Kansas Medical Center, Kansas City, Kansas Department of Internal Medicine, Division of Nephrology and Hypertension, University of Kansas Medical Center, Kansas City, Kansas
    J Am Soc Nephrol 27:305-13. 2016
    ..Increased TMAO concentrations correlate with coronary atherosclerosis burden and may associate with long-term mortality in patients with CKD undergoing coronary angiography. ..
  2. pmc Decreased conversion of 25-hydroxyvitamin D3 to 24,25-dihydroxyvitamin D3 following cholecalciferol therapy in patients with CKD
    Jason R Stubbs
    The Kidney Institute, University of Kansas Medical Center, Kansas City, Kansas
    Clin J Am Soc Nephrol 9:1965-73. 2014
    ....
  3. pmc Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease
    Jason R Stubbs
    The Kidney Institute, University of Kansas Medical Center, Kansas City, KS 66160, USA
    J Bone Miner Res 27:38-46. 2012
    ..Elevations in FGF23 and PTH coincide with an increase in urinary phosphate excretion that likely prevents the early onset of hyperphosphatemia in the face of increased bone turnover and a progressive decline in functional renal mass...
  4. doi request reprint Is fibroblast growth factor 23 a harbinger of mortality in CKD?
    Jason R Stubbs
    Division of Nephrology and Hypertension, University of Kansas Medical Center, 3901 Rainbow Blvd, Mail Stop 3002, Kansas City, KS 66160, USA
    Pediatr Nephrol 27:697-703. 2012
    ..This review highlights our current understanding of the regulation and function of FGF23 and examines the existing literature linking FGF23 with adverse outcomes...
  5. pmc Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD
    Jason R Stubbs
    3901 Rainbow Boulevard, MS 3002, Kansas City, KS 66160, USA
    J Am Soc Nephrol 21:353-61. 2010
    ..These data suggest that nutritional vitamin D therapy has a biologic effect on circulating monocytes and associated inflammatory markers in patients with ESRD...
  6. doi request reprint Does it matter how parathyroid hormone levels are suppressed in secondary hyperparathyroidism?
    Jason R Stubbs
    Division of Nephrology and Hypertension and The Kidney Institute, University of Kansas Medical Center, Kansas City, Kansas, USA
    Semin Dial 24:298-306. 2011
    ..We also examine the potential nonclassical effects of these therapies on the renin-angiotensin-aldosterone system, proteinuria, vascular calcification, fibroblast growth factor-23, inflammation, and overall survival...
  7. pmc Dietary phosphate restriction suppresses phosphaturia but does not prevent FGF23 elevation in a mouse model of chronic kidney disease
    Shiqin Zhang
    The Kidney Institute, University of Kansas Medical Center, Kansas City, Kansas, USA
    Kidney Int 84:713-21. 2013
    ..Thus, dietary phosphate restriction reduces the fractional excretion of phosphorus independent of serum FGF23 levels in mice with CKD...
  8. ncbi request reprint Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice
    Jason R Stubbs
    The Kidney Institute, University of Kansas Medical Center, Kansas City, KS 66160, USA
    J Am Soc Nephrol 18:2116-24. 2007
    ....
  9. ncbi request reprint Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D
    Shiguang Liu
    Department of Internal Medicine and the Kidney Institute, University of Kansas Medical Center, 3901 Rainbow Boulevard, Room 6020 WHE, MS 3018, Kansas City, KS 66160, USA
    J Am Soc Nephrol 17:1305-15. 2006
    ..The physiologic role of FGF23 may be to act as a counterregulatory phosphaturic hormone to maintain phosphate homeostasis in response to vitamin D...
  10. pmc FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy
    Chad D Touchberry
    Muscle Biology Group, School of Medicine, University of Missouri Kansas City, Kansas City, MO 64108, USA
    Am J Physiol Endocrinol Metab 304:E863-73. 2013
    ..In conclusion, FGF23 is a novel bone/heart endocrine factor and may be an important mediator of cardiac Ca(2+) regulation and contractile function during chronic kidney disease...
  11. ncbi request reprint Fibroblast growth factor 23: uremic toxin or innocent bystander in chronic kidney disease?
    Jason R Stubbs
    Division of Nephrology and Hypertension, University of Kansas Medical Center, Kansas City, KS, USA
    Nephrol News Issues 23:33-4, 36-7. 2009
    ....